

ASLAN to present at 9th Annual SVB LEERINK global healthcare conference

24 February 2020 | News

ASLAN Pharmaceuticals is a clinical-stage immunology and oncology-focused biopharmaceutical company developing innovative product candidates that target significant unmet medical needs and global market opportunities



ASLAN Pharmaceuticals Limited, clinical-stage immunology and oncology-focused biopharmaceutical company, on 24th Feb 2020 announced its presentation at the 9th Annual SVB Leerink Global Healthcare Conference. Dr Carl Firth, Chief Executive Officer, and Stephen Doyle, Chief Business Officer, is scheduled to present an overview of the company on Wednesday, 26 February 2020 at 09:00am EST. The conference will be held on 25-27 February 2020 in New York.